Intellia Therapeutics (NTLA) News Today $12.18 +0.10 (+0.83%) (As of 12/20/2024 05:45 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Barclays PLC Acquires 44,022 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)Barclays PLC lifted its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 17.7% in the third quarter, according to its most recent filing with the SEC. The firm owned 292,795 shares of the company's stock after acquiring an additional 44,022 shares during the period.December 20 at 4:24 AM | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Sets New 12-Month Low - Here's What HappenedIntellia Therapeutics (NASDAQ:NTLA) Hits New 52-Week Low - Should You Sell?December 18 at 5:37 PM | marketbeat.comState Street Corp Buys 780,754 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)State Street Corp boosted its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 17.9% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,143,534 shares of the comDecember 16, 2024 | marketbeat.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Short Interest UpdateIntellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) was the target of a significant increase in short interest in November. As of November 30th, there was short interest totalling 18,910,000 shares, an increase of 15.5% from the November 15th total of 16,370,000 shares. Based on an average daily trading volume, of 2,410,000 shares, the days-to-cover ratio is currently 7.8 days.December 15, 2024 | marketbeat.comWellington Management Group LLP Has $13.25 Million Stock Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)Wellington Management Group LLP lowered its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 17.5% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 644,763 shares of the company's stock afteDecember 15, 2024 | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Stock Price Down 4.2% - Should You Sell?Intellia Therapeutics (NASDAQ:NTLA) Trading Down 4.2% - Here's WhyDecember 13, 2024 | marketbeat.comWhy Intellia Therapeutics (NTLA) Is the Worst ARK Stock to Buy According to Short SellersDecember 12, 2024 | msn.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Given Average Rating of "Moderate Buy" by AnalystsShares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) have received a consensus rating of "Moderate Buy" from the eighteen ratings firms that are presently covering the stock, Marketbeat.com reports. Six investment analysts have rated the stock with a hold rating, eleven have issuedDecember 11, 2024 | marketbeat.comTwo Sigma Advisers LP Has $21.12 Million Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)Two Sigma Advisers LP boosted its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 33.5% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,027,617 shares of the company's stock after purchasing an additiDecember 9, 2024 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Reduces Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC reduced its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 10.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 460,012 shareDecember 9, 2024 | marketbeat.comFmr LLC Buys 111,104 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)Fmr LLC boosted its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 5.0% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,339,522 shares of the company's stock after purchasing an additional 111,104 shares duDecember 8, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Acquires 37,714 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)Charles Schwab Investment Management Inc. raised its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 4.8% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 827,545 shares of the company's stock after puDecember 8, 2024 | marketbeat.comBenjamin Edwards Inc. Acquires 57,253 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)Benjamin Edwards Inc. lifted its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 13,762.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 57,669 shares of the company's stock after buying anDecember 7, 2024 | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Stock Price Up 7.5% - Time to Buy?Intellia Therapeutics (NASDAQ:NTLA) Trading Up 7.5% - Still a Buy?December 6, 2024 | marketbeat.comVerition Fund Management LLC Increases Stock Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)Verition Fund Management LLC lifted its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 116.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 94,426 shares of the company's stock after purchaDecember 6, 2024 | marketbeat.com128,569 Shares in Intellia Therapeutics, Inc. (NASDAQ:NTLA) Acquired by Patient Square Capital LPPatient Square Capital LP acquired a new stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 128,569 shares of the company's stock, vaDecember 4, 2024 | marketbeat.comChevy Chase Trust Holdings LLC Sells 231,592 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)Chevy Chase Trust Holdings LLC lowered its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 22.2% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 811,033 shares of the company's sDecember 4, 2024 | marketbeat.comPDT Partners LLC Sells 212,406 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)PDT Partners LLC reduced its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 93.5% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 14,814 shares ofDecember 4, 2024 | marketbeat.comBNP Paribas Financial Markets Has $5.06 Million Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)BNP Paribas Financial Markets raised its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 88.0% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 246,362 shares of the company's stock after buying an additional 115,351 shaDecember 4, 2024 | marketbeat.comIntellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)December 3, 2024 | globenewswire.comPromising Outlook for Intellia Therapeutics’ Nex-z in ATTR-CM Treatment Backed by Safety and Patient InterestNovember 26, 2024 | markets.businessinsider.comIntellia announces FDA granted RMAT designation to nexiguran ziclumeranNovember 26, 2024 | markets.businessinsider.com2 Penny Stocks That Wall Street Predicts Will Soar 306% to 1,183% in 2025November 26, 2024 | msn.comIntellia Gets RMAT Designation From FDA For Nex-z In ATTR Amyloidosis With Polyneuropathy; Stock UpNovember 25, 2024 | markets.businessinsider.comIntellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with PolyneuropathyNovember 25, 2024 | globenewswire.comDown 33% in 1 Month, Should You Buy the Dip With Intellia Therapeutics Stock?November 22, 2024 | fool.comEquities Analysts Offer Predictions for NTLA FY2025 EarningsIntellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) - Analysts at Chardan Capital reduced their FY2025 earnings estimates for Intellia Therapeutics in a research note issued to investors on Monday, November 18th. Chardan Capital analyst Y. Livshits now forecasts that the company will post earNovember 21, 2024 | marketbeat.comIntellia Therapeutics Announces Promising CRISPR Therapy ResultsNovember 20, 2024 | finance.yahoo.comCathie Wood’s ARK Investment buys 223.5K shares of Intellia Therapeutics todayNovember 20, 2024 | markets.businessinsider.comIntellia’s gene editing therapy shows early potential in rare heart conditionNovember 19, 2024 | msn.comIntellia Therapeutics price target lowered to $70 from $80 at Wells FargoNovember 19, 2024 | markets.businessinsider.comIntellia Therapeutics’ NTLA-2001 Shows Promising Potential with Positive Phase 1 Data and Accelerated Phase 3 EnrollmentNovember 19, 2024 | markets.businessinsider.comIntellia Therapeutics' Gene Therapies Fall Short Of Breakthroughs (Rating Downgrade)November 19, 2024 | seekingalpha.comWells Fargo & Company Issues Pessimistic Forecast for Intellia Therapeutics (NASDAQ:NTLA) Stock PriceWells Fargo & Company reduced their target price on shares of Intellia Therapeutics from $80.00 to $70.00 and set an "overweight" rating for the company in a research note on Monday.November 18, 2024 | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Sees Unusually-High Trading Volume Following Analyst UpgradeIntellia Therapeutics (NASDAQ:NTLA) Sees Strong Trading Volume After Analyst UpgradeNovember 18, 2024 | marketbeat.comIntellia Therapeutics' (NTLA) Neutral Rating Reaffirmed at WedbushWedbush reissued a "neutral" rating and issued a $14.00 target price on shares of Intellia Therapeutics in a research report on Monday.November 18, 2024 | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Given Neutral Rating at William BlairWilliam Blair restated a "neutral" rating and issued a $14.00 price target on shares of Intellia Therapeutics in a research note on Monday.November 18, 2024 | marketbeat.comChardan Capital Boosts Intellia Therapeutics (NASDAQ:NTLA) Price Target to $91.00Chardan Capital upped their target price on Intellia Therapeutics from $88.00 to $91.00 and gave the stock a "buy" rating in a report on Monday.November 18, 2024 | marketbeat.comIntellia Therapeutics: Buy Rating Driven by Promising Efficacy and Safety of Nex-Z TreatmentNovember 17, 2024 | markets.businessinsider.comIntellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) AmyloidosisNovember 16, 2024 | globenewswire.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Average Rating of "Moderate Buy" from BrokeragesShares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the sixteen brokerages that are covering the company, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a hold rating, ten have issuNovember 16, 2024 | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Reaches New 1-Year Low - Here's WhyIntellia Therapeutics (NASDAQ:NTLA) Reaches New 1-Year Low - What's Next?November 15, 2024 | marketbeat.comSumitomo Mitsui Trust Group Inc. Sells 108,290 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)Sumitomo Mitsui Trust Group Inc. cut its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 3.3% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 3,149,399 shares of the company's stock afNovember 15, 2024 | marketbeat.comIntellia Therapeutics: Buy Rating Affirmed on Promising NTLA-2001 Data and Upcoming CatalystsNovember 14, 2024 | markets.businessinsider.comIntellia Therapeutics (NTLA) Gets a Buy from Truist FinancialNovember 12, 2024 | markets.businessinsider.comIntellia Therapeutics price target lowered to $60 from $70 at OppenheimerNovember 11, 2024 | markets.businessinsider.comOppenheimer Lowers Intellia Therapeutics (NASDAQ:NTLA) Price Target to $60.00Oppenheimer cut their price objective on Intellia Therapeutics from $70.00 to $60.00 and set an "outperform" rating for the company in a report on Monday.November 11, 2024 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA), Veeva Systems (VEEV) and Neuren Pharmaceuticals Limited (OtherNURPF)November 11, 2024 | markets.businessinsider.comIntellia Therapeutics: Q3 Earnings Report Puts Phase II Results In FocusNovember 11, 2024 | seekingalpha.com3 Fast-Growing Stocks Analysts See Doubling in PriceClinical-stage biotech firms often have massive upside potential, but much of that possible success hinges on successful trials and product launches.November 11, 2024 | marketbeat.com Get Intellia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter. Email Address URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight. >> Register for the Workshop Now NTLA Media Mentions By Week NTLA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NTLA News Sentiment▼0.640.61▲Average Medical News Sentiment NTLA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NTLA Articles This Week▼57▲NTLA Articles Average Week Get Intellia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Viking Therapeutics News TG Therapeutics News BridgeBio Pharma News Crinetics Pharmaceuticals News Krystal Biotech News Arcellx News ADMA Biologics News Ultragenyx Pharmaceutical News Apellis Pharmaceuticals News Biohaven News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NTLA) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intellia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intellia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NTLA Stock Alerts